The role of optimal cut-off diagnosis in 11C-methionine PET for differentiation of intracranial brain tumor from non-neoplastic lesions before treatment.

MLA

Yamaki, Tomohiro, et al. “The Role of Optimal Cut-off Diagnosis in 11C-Methionine PET for Differentiation of Intracranial Brain Tumor from Non-Neoplastic Lesions before Treatment.” Clinical Imaging, vol. 92, Dec. 2022, pp. 124–30. EBSCOhost, https://doi.org/10.1016/j.clinimag.2022.10.007.

APA

Yamaki, T., Higuchi, Y., Yokota, H., Iwadate, Y., Matsutani, T., Hirono, S., Sasaki, H., Sasao, R., Toda, M., Onodera, S., Oka, N., & Kobayashi, S. (2022). The role of optimal cut-off diagnosis in 11C-methionine PET for differentiation of intracranial brain tumor from non-neoplastic lesions before treatment. Clinical Imaging, 92, 124–130. https://doi.org/10.1016/j.clinimag.2022.10.007

Chicago

Yamaki, Tomohiro, Yoshinori Higuchi, Hajime Yokota, Yasuo Iwadate, Tomoo Matsutani, Seiichiro Hirono, Hikaru Sasaki, et al. 2022. “The Role of Optimal Cut-off Diagnosis in 11C-Methionine PET for Differentiation of Intracranial Brain Tumor from Non-Neoplastic Lesions before Treatment.” Clinical Imaging 92 (December): 124–30. doi:10.1016/j.clinimag.2022.10.007.